Strides Pharma Q1 FY27 Results: Revenue Rises 13% YoY, Net Profit Jumps 57%

Strides Pharma Science reported a steady financial performance for the first quarter of FY27, with revenue increasing 13% year-on-year (YoY) to ₹12,654 million. The growth was mainly supported by strong performance in markets outside the US.

The company announced its financial results for the quarter ended June 30, 2026, on July 31, 2026.

Revenue Growth Driven by International Markets

Strides' Ex-US business grew 17% YoY to ₹5,875 million ($63 million), driven by healthy demand across several international markets.

Meanwhile, the US business remained stable, with revenue rising 4% YoY to ₹6,282 million ($68 million).

Profitability Improves Despite Higher Costs

The company reported EBITDA of ₹2,298 million, up 5.4% YoY. However, EBITDA growth was affected by approximately ₹131 million in additional freight and operating costs due to ongoing geopolitical disruptions.

The EBITDA margin stood at 18.2% during the quarter.

Operational profit after tax (PAT) increased 8% YoY to ₹1,231 million, while operational earnings per share (EPS) rose to ₹13.4.

Reported PAT jumped 56.7% YoY to ₹1,655 million, and reported EPS increased to ₹17, supported by an exceptional gain from the sale of a majority stake in Pivot Path.

Key Financial Highlights

Pivot Path Stake Sale Unlocks Value

During the quarter, Strides unlocked ₹1,000 million by selling a majority stake in Pivot Path, its captive Global Capability Centre (GCC). The company said it continues to retain a meaningful stake in the business, allowing it to benefit from its future growth.

Debt Reduction and Sustainability Progress

Strides reduced its net debt by ₹119 million during the quarter. Its Net Debt-to-EBITDA ratio improved to 1.52x, despite increased working capital requirements.

The company also improved its EcoVadis sustainability score to 68 out of 100, marking a 19-point improvement compared with the previous year.

Management Commentary

Managing Director and Group CEO Badree Komandur said the company delivered a strong start to FY27, supported by robust growth in international markets and disciplined execution.

He added that although geopolitical challenges increased operating and freight costs during the quarter, the company remains focused on improving efficiency, controlling costs and delivering sustainable long-term growth.

About Strides Pharma

Strides Pharma Science is a Bengaluru-based global pharmaceutical company listed on the BSE and the NSE. The company focuses on manufacturing complex pharmaceutical products and operates manufacturing facilities in India, Italy, Kenya and the United States. Its products are sold in more than 100 countries.

Strides Pharma Share Price Movement

On July 31, 2026, Strides Pharma Science share price (NSE: STAR ) was trading at ₹1,023.90, down 4.56% or ₹48.90 in the intraday session. The stock opened at ₹1,073.60 and touched an intraday high of ₹1,100 before falling to a low of ₹1,011.10. 

Read More: Best Gold Stocks in July 2026 Based on 5‑Year CAGR: Sky Gold and Diamonds, Laxmi Goldorna House and More!

Conclusion

Strides Pharma delivered a solid start to FY27, with double-digit revenue growth and a sharp rise in reported profit. Strong performance in international markets, improved profitability and continued efforts to strengthen its balance sheet position the company well for sustainable growth despite global cost pressures.

For daily market updates and regular stock market news in Hindi, stay tuned to Angel One's share market news in Hindi. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks. Read all related documents carefully before investing.